Search
Now showing items 1-2 of 2
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
(
MDPI
, 2024 , Article Review)
Immunotherapy is now established as a potent therapeutic paradigm engendering antitumor immune response against a wide range of malignancies and other diseases by modulating the immune system either through the stimulation ...